



Quest
LABORATORIES LIMITED

(Formerly known as Quest Laboratories Pvt. Ltd.)

CIN No.: U24232MP1998PLC012850

July 24, 2025

To,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G-Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai – 400051
Maharashtra, India.

NSE Symbol: QUESTLAB

Sub: Outcome of Board meeting held today i.e. on July 24, 2025.

Dear Sir/Madam,

With reference to the captioned subject, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e. July 24, 2025, has inter-alia:

1. considered and approved the Un- Audited Financial Results of the Company for the Quarter ended June 30, 2025, in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Copy of Un- audited Financial Results of the Company for the Quarter ended June 30, 2025, along with Limited Review Report issued by the statutory Auditors for the said quarter are enclosed herewith and marked as Annexure-1.

The results are also being uploaded on the Company's website at www.questlabltd.com

The meeting of the Board of Directors commenced at 12:00 P.M. and concluded at 03:50 P.M.

This is for your information and records.

Thanking you,
Yours faithfully,

For Quest Laboratories Limited

Anil Kumar Sabarwal
Managing Director
DIN:00646133

Encl: A/a

Regd. Off. & Plant : Plot No. 45, Opp. Kissan Pipe Unit 4, Sector III, Pithampur Dist. Dhar (MP) 454775.



cmd@questlabltd.com
sales@questlabltd.com
investor@questlabltd.com



www.questlabltd.com
GST No.: 23AAACQ1040R1ZH



+91 9329095934
+91 7999149001
(F) +91 07292292374

C. H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.

S. C. PADLIYA M. Com., F. C. A.

VIPUL PADLIYA B. Com., F. C. A.



H.O. : 90, Dawa Bazar, 2nd Floor, 13-14

RNT Marg, Indore - 452 001 (INDIA)

Office : +91 731 2704343

B.O. : 101, Pragati Appartment, Opp. Krashi

Mandi, Pratapnagar (Raj.)-312605

Tel. : +1478-22624

Official webpage : www.chpadliya.com

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review report to the Board of Directors of **QUEST LABORATORIES LIMITED**,

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **QUEST LABORATORIES LIMITED** ("the Company") for the quarter ended **30th June, 2025**, and year to date results for the period **1st April, 2025 to 30th June, 2025**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Listing Regulations) including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the accounting principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of

C.H. PADLIYA & Co.

Chartered Accountants

Firm registration no.003151C



VIPUL PADLIYA

Partner

Membership no. 409165

UDIN: 25409165BMORDY8240

Date: 24th July, 2025

Place: Indore

QUEST LABORATORIES LIMITED

Regd. Office : Plot No. 45 Sector III Pithampur, Pithampur, Dhar, Dhar, Madhya Pradesh, India, 454775 Phone: 07292-292374

E-Mail: investors@questlabltd.com, Web : <https://www.questlabltd.com/>, CIN: U24232MP1998PLC012850

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

Sr. No.	Particulars	Quarter Ended			Year Ended	
		(Unaudited)	Unaudited	(Audited)	(Audited)	(Audited)
		30 June 2025	31 March 2025	30 June 2024	31 March 2025	31 March 2024
1	Income					
	(a) Revenue from Operations	2,318.48	4,645.19	1,525.13	10,391.48	8,256.28
	(b) Other Income	185.46	341.30	16.33	429.48	22.91
	Total Income from Operation	2,503.94	4,986.49	1,541.46	10,820.96	8,279.19
2	Expenses:					
	a) Cost of Materials consumed	1,936.63	4,291.78	1,215.43	8,327.66	5,228.95
	b) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade	(158.15)	(9.87)	(57.17)	(411.81)	(4.44)
	c) Employee Benefits Expenses	104.02	162.31	72.11	427.71	448.30
	d) Finance Costs	63.60	36.69	12.78	90.55	77.92
	e) Depreciation and Amortisation expense	20.64	18.62	14.95	63.60	56.78
	f) Other expenses	22.11	70.60	93.15	312.97	878.77
	Manufacturing & Operating Expenses	32.66	49.72	23.72	141.97	148.32
	Total Expenses	2,021.51	4,619.85	1,374.97	8,952.65	6,834.60
3	Profit / (Loss) from ordinary activities before Exceptional items and tax (1-2)	482.43	366.64	166.49	1,868.31	1,444.59
4	Exceptional Items	-	-	-	-	-
5	Profit / (Loss) before tax (3 - 4)	482.43	366.64	166.49	1,868.31	1,444.59
6	Tax Expense					
	- Current tax	(72.00)	(125.31)	(18.83)	(457.18)	(420.66)
	- Deferred tax	-	(47.63)	-	(54.60)	(14.54)
	Total Tax Expenses	(72.00)	(172.94)	(18.83)	(511.78)	(435.20)
7	Profit / (Loss) for the period from continuing operation (5 - 6)	410.43	193.70	147.66	1,356.53	1,009.39
8	Profit / (Loss) from discontinued operation	-	-	-	-	-
9	Tax expenses for discontinued operation	-	-	-	-	-
10	Profit / (Loss) from discontinued operation (after tax) (8-9)	-	-	-	-	-
11	Profit / (Loss) for the period (7+10)	410.43	193.70	147.66	1,356.53	1,009.39
12	Other Comprehensive Income, net of income tax					
	A (i) Items that will not be reclassified to Profit or Loss	-	0.15	(0.15)	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income, net of income tax	-	0.15	(0.15)	-	-
13	Total Comprehensive Income for the period (11+12)	410.43	193.85	147.51	1,356.53	1,009.39
14	Paid-up equity share capital (face value of INR 10/- per share)	1,638.72	1,638.72	1,638.72	1,638.72	1,193.76
15	Other Equity (excluding Revaluation Reserve)	6,963.09	6,541.62	5,330.13	6,541.62	1,673.05
16	Earning per share (of INR 10/- each) (not annualised)					
	Basic/ Diluted EPS	2.50	1.18	0.90	8.28	6.16

Notes:	
1)	The above results for the Quarter ended June 30, 2025 have been reviewed by the Audit Committee in it's meeting held on July 24, 2025 and taken on record by the Board of Directors in its meeting held on July 24, 2025.
2)	The statutory auditors has expressed an unmodified audit opinion.
3)	The above Financial Result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
4)	Segment-wise reporting as defined in Ind AS-108 is not applicable, since the entire operation of the Company relates to only one segment.
5)	During the quarter ending 30.06.2025, the Company has acquired land at Indore admeasuring 0.107 Hectare for INR 321.20 Lakhs for expansion of its manufacturing activities.
6)	The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

Place: Pithampur, Dhar
Date: 24.07.2025

On behalf of the Board of Directors
For Quest Laboratories Limited

Anil Sabarwal
Managing Director
(DIN-00646133)

